Suven Pharmaceuticals Limited (NSE:SUVENPHAR) — Market Cap & Net Worth
Market Cap & Net Worth: Suven Pharmaceuticals Limited (SUVENPHAR)
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) has a market capitalization of $4.40 Billion (Rs406.97 Billion) as of September 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #3883 globally and #167 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Suven Pharmaceuticals Limited's stock price Rs1063.80 by its total outstanding shares 382567008 (382.57 Million). Also see how large is Suven Pharmaceuticals Limited's balance sheet for a full breakdown of the balance sheet.
Suven Pharmaceuticals Limited Market Cap History: 2020 to 2025
Suven Pharmaceuticals Limited's market capitalization history from 2020 to 2025. Data shows growth from $1.83 Billion to $4.40 Billion (41.59% CAGR). Also see SUVENPHAR cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Suven Pharmaceuticals Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.06 Trillion | 0.14% | #155 of 500 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.14 Trillion | 0.39% | #83 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.15 Trillion | 0.14% | #153 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$406.30 Billion | 1.08% | #12 of 250 |
Weight: Suven Pharmaceuticals Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Suven Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Suven Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Suven Pharmaceuticals Limited for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.37x
Suven Pharmaceuticals Limited's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.66x
Suven Pharmaceuticals Limited's market cap is 1.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.83 Billion | $8.07 Billion | $3.17 Billion | 0.23x | 0.58x |
| 2021 | $2.01 Billion | $9.80 Billion | $3.62 Billion | 0.20x | 0.55x |
| 2022 | $2.05 Billion | $12.90 Billion | $4.54 Billion | 0.16x | 0.45x |
| 2023 | $2.99 Billion | $13.40 Billion | $4.11 Billion | 0.22x | 0.73x |
| 2024 | $4.71 Billion | $10.51 Billion | $3.00 Billion | 0.45x | 1.57x |
| 2025 | $4.40 Billion | $11.98 Billion | $2.65 Billion | 0.37x | 1.66x |
Competitor Companies of SUVENPHAR by Market Capitalization
Companies near Suven Pharmaceuticals Limited in the global market cap rankings as of September 18, 2026. Review Suven Pharmaceuticals Limited tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Suven Pharmaceuticals Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Suven Pharmaceuticals Limited Historical Marketcap From 2020 to 2025
Between 2020 and today, Suven Pharmaceuticals Limited's market cap moved from $1.83 Billion to $ 4.40 Billion, with a yearly change of 41.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Rs4.40 Billion | -6.58% |
| 2024 | Rs4.71 Billion | +57.55% |
| 2023 | Rs2.99 Billion | +46.05% |
| 2022 | Rs2.05 Billion | +1.97% |
| 2021 | Rs2.01 Billion | +9.47% |
| 2020 | Rs1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 15th, 2026 the market cap of Suven Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.40 Billion USD |
| MoneyControl | $4.40 Billion USD |
| MarketWatch | $4.40 Billion USD |
| marketcap.company | $4.40 Billion USD |
| Reuters | $4.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more